Is T-DXd Worth the Risk? Evaluating Benefit vs Toxicity

ILD, fatigue, cytopenias — real toxicities with real management strategies.

This clip explores why, despite these risks, the benefit-to-risk ratio strongly favors T-DXd + pertuzumab for many patients.